Article Details

Zacks Investment Research Downgrades Cellectis (NASDAQ:CLLS) to Sell

Retrieved on: 2018-03-01 23:49:55

Tags for this article:

Click the tags to see associated articles and topics

Zacks Investment Research Downgrades Cellectis (NASDAQ:CLLS) to Sell. View article details on hiswai:

Excerpt

<div><b>Millennium Management</b> LLC grew its position in shares of Cellectis by 1,356.2% during the 4th quarter. <b>Millennium Management</b> LLC now owns 104,290 shares of the biotechnology company's stock worth $3,040,000 after buying an additional 97,128 shares during the period. Bain Capital Public ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo